Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I could be wrong, but I think we've discussed Advent costs in the past.
I thought the talk at the time was that Advent would of course get the production costs and on top of that another 15% of that amount as margin.
imo
Anyone?
GLTU
Captain,
I may be too gullible, but I certainly can't imagine LP would screw us over like that.
Not after everything we've been through with her.
IMO of course.
beartrap,
In my 45 years of trade fair experience, I have never heard of, let alone seen, something like this.
GLTU
Post
See new posts
Conversation
Peter Davis reposted
hoffmann6383
@hoffmann6383
🧑⚖️Harrington Discovery Update: Market Makers are slowly losing the battle to protect the identity of third parties involved in spoofing🧑⚖️
$NWBO $BOC
@CIBCCM
@VirtuFinancial
The Case: Harrington Global Opportunity Fund, Limited v. BofA Securities, Inc., 1:21-cv-00761, (S.D.N.Y.)
Plaintiff: Harrington Global Opportunity Fund, Limited
Defendant Market Makers: TD Securities (USA) LLC, TD Securities, Inc., SG Americas Securities, LLC, Merrill Lynch Canada Inc., CIBC World Markets Inc., and BofA Securities, Inc.
In federal court the parties are obligated to meet and confer regarding any discovery issues before bringing the matter to the Court’s attention. On April 17th the Plaintiff in the above case requested an extension of the fact discovery timeline (Docket Entry #214). The plaintiff explained that Defendant had not complied with discovery and summarized negotiations between the parties to resolve said discovery disputes. In this post I’ll quickly address some of those negotiations.
Docket Entry #214: https://courtlistener.com/docket/46947528/harrington-global-opportunity-fund-limited-v-bofa-securities-inc/
✅Plaintiff seeks communications regarding Defendants' algorithms
"Defendants also have failed to produce documents and communications concerning algorithms used by customers or Defendants in the trading at issue (the only partial exception is Merrill, which produced a small number of documents concerning trading algorithms recently, after resisting production for months)."
✅Plaintiff seeks communications between Defendants' customers and Defendants
"These open discovery issues—which have resulted in Defendants having produced virtually zero emails with customers or about customers concerning their trading behavior in Concordia—must be resolved well before depositions commence."
✅Market Makers other than the listed Defendants are involved in the alleged spoofing
"And even in doing so, CIBC confirmed on the same day that it is refusing to produce data reflecting approximately 21 million shares of Concordia executed through Virtu, a third-party broker, and transferred to CIBC during the Relevant Period."
✅Virtu and other non-defendant market makers have received, or are likely to receive, subpoena(s)
"In light of these developments, Harrington now must (1) confer with CIBC regarding the data that CIBC has refused to produce (among other open issues); (2) analyze the existing dataset to confirm it is in fact complete; (3) perform a millisecond matching analysis of the full dataset to identify orders for deanonymization pursuant to the Court’s March 18 and March 21 Orders; (4) meet and confer with CIBC on that issue as needed; (5) after receiving the deanonymized identities, evaluate any coordinated spoofing activity, including through third-party discovery; and (6) prepare for and take fact depositions." (emphasis added)
"Moreover, as the Court will recall, Merrill discovered only in January 2024—as a result of an admitted “screw up”—that the vast majority of customer trade and order data it had yet to produce was held by a third party.…and Harrington has issued a subpoena to the third party." (emphasis added)
✅Customers are likely to receive subpoena(s)
"But some of the most promising potential compromises the parties have discussed will require Harrington to first obtain and then review the complete trade and order data, obtain deanonymization of certain trading activity as ordered by the Court, and attempt to tailor document requests to customers and accounts believed to be involved in spoofing." (emphasis added)
7:35 PM · Apr 18, 2024
·
5,060
Views
Post
See new posts
Conversation
Peter Davis
@peter_brit
#dcvax $nwbo #gbm
Nonrandomised controlled trial in recurrent glioblastoma patients: the promise of autologous tumour lysate-loaded dendritic cell vaccination Francesco Pasqualetti © The Author(s) 2023 1,2,4✉ and Sofia Zanotti 3,4
Again we have failures to disclose conflict of interests by another Doctor who specialises in Radiology, criticizes DCVax results and yet declares "no conflict of Interests"
We know that multiple Doctors specializing in Radiology have come out to criticize DCVax as they see their jobs under threat, this does not give them the right however, not to abide by their Hippocratic oath and not to disclose the fact their earnings come from a treatment that DCVax technology could potentially replace.
s41416-023-02194-1.pdf (http://nature.com)
Radio-chemotherapy with Temozolomide in Elderly Patients with Glioblastoma. A Mono-institutional Experience | Anticancer Research (http://iiarjournals.org)
Thanks Captain.
GLTU
Thank you for this answer hyperopia.
I have to say that I already doubted whether it was intended for me.
I probably just reacted too quickly.
And, indeed, those doctors should be deeply ashamed.
Sorry for the confusion.
Best to you.
Totally agree Chiugray.
Unfortunately, I have experienced this several times on the American stock exchanges.
I have become wise through trial and error and most likely know what awaits me with this NWBO adventure: Lots of good and financial carefree.
Thank you for your response.
Best to you.
This article states: "Antonio Chiocca was being interviewed in a podcast where he (and the interviewer) continues to link DCVax to a "failed phase 3 trial"
What does this have to do with John Fortunato ( the interviewer)?
I don't understand your aggression.
GLTU
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174216659
We will therefore see the necessary 5 year OS figures in the 2nd half of 2029.
Tommy Bax 🇬🇧 🇹🇼
@TommyBaxendale
@EAChiocca
is definitely upholding his Hippocratic oath and having peers/ general public question his work.
Nothing to hide whatsoever… although I just found he blocked me because I reasonably questioned his paper last year.
Time for others to question him I think!
$NWBO
12:15 PM · Apr 10, 2024
·
1,942
Views
Kauri Capital
@KauriCapital
·
11h
Disclosure of Potential Conflicts of Interest
E.A. Chiocca has an ownership interest (including patents) and is a consultant/advisory board member of DNAtrix. S.D. Rabkin has an ownership interest (including patents) as coinventor on oncolytic HSV patents.
Peter Davis
@peter_brit
#dcvax $nwbo #gbm
Truly unbelievable....
Just as Neuro-oncology published the correction to the article attacking DCVax results with flawed and incorrect information whilst the four authors failed to disclose their conflict of Intersts, on March 8th It turns out one of those authors E Antonio Chiocca was being interviewed in a podcast where he (and the interviewer) continues to link DCVax to a "failed phase 3 trial"
He is obviously that desperate to project DCVax as a failed treatment regardless of the evidence to the contrary!
I have notified #nwbo
https://soc-neuro-onc.libsyn.com/website/immunotherapy-for-glioblastoma-lessons-learned
Thanks Captain.
GLTU
3 days already.
GLTU
I see that your meeting room, investorvillage, has disappeared from the internet.
Or deleted?
What bad luck for you and your friends, right?
Can't these people be pilloried by this or that person?
Now or later?
It's a shame!
GLTU
Post
See new posts
Conversation
Peter Davis
@peter_brit
·
1h
#dcvax $nwbo #gbm
First Published: 23 November 2023. it has taken nearly five months of likely screaming and kicking' and throwing their "teddy out of their cot" But the authors..
Ethan Chen, Alexander L Ling, David A Reardon, E Antonio Chiocca
all of who failed to disclose…
Show more
d_stock
@d_stock07734
·
1h
The paper needs further modifications to disclose the fact that Dr. David Reardon is working as SAB member of Immunomic Theraleutics.
Peter Davis
@peter_brit
#dcvax $nwbo #gbm
As you are aware and have pointed out previously the problem is much greater than just Reardon, I have posted on numerous occasions about failures to disclose conflict of interests by all these authors. The fact it took nearly five months for this correction without any apology speaks volumes.
Thanks Peter (pgsd) !
Peter Davis
@peter_brit
·
1h
#dcvax $nwbo #gbm
First Published: 23 November 2023. it has taken nearly five months of likely screaming and kicking' and throwing their "teddy out of their cot" But the authors..
Ethan Chen, Alexander L Ling, David A Reardon, E Antonio Chiocca
all of who failed to disclose…
https://academic.oup.com/neuro-oncology/article/26/4/779/7477448
Peter Davis
@peter_brit
·
21m
#dcvax $nwbo #gbm
Quote
Dr. Thomas Ichim
@exosome
·
15h
The $NWBO technology is so exciting because it can be plugged into so many other medical areas besides #oncology
Bio99
@BIO99_BIO99
·
9h
Love this! DCVax, DCVax and … DCVax. $NWBO
Quote
National Cancer Institute
@theNCI
·
9h
Replying to @theNCI and @NCIDirector
“We have a lot to be excited about in all areas of cancer research” today, @NCIDirector says. For example, immunotherapies, new targeted therapies, and effective treatments for the hardest-to-treat
I don't know if I'm the only one, but investor village has been down for 2 days.
The website cannot be reached by me.
Anyone?
Post
See new posts
Conversation
annie post
@apwriter
·
9h
5 BP+ partnerships @ $15B each is doable.
Add in all of LIau’s “Amazon” model of “just-in time,” localized, Flaskworks Manu at eg. Walgreens/hospitals/cancer centers. ETC.
Suddenly TUMOR-AGNOSTIC (~90% of cancers) $nwbo comparison to NVIDA’s $1 to $7k SP is not so outrageous.
Quote
d_stock
@d_stock07734
·
18h
Replying to @dcvaxdaw
But NWBO is a startup that can cure cancer. Is there a BP that can afford it?
d_stock
@d_stock07734
Here are the major players of PD-1 and PD-L1 inhibitors and the market size for PD-1 and PD-L1 inhibitors is about $40b in 2023. All these PD1/L1 inhibitors lack of efficacy for cold tumors which account for 80% of all solid tumors. DCVax-L can turn cold tumor into hot one so that these BPs can find a much larger market for their products. So $15B each can be a reasonable number.
Merck & Co., Inc.,
Hoffmann-La Roche Ltd,
AstraZeneca
Novartis AG
Sanofi
Lilly
Bristol Myers Squibb (BMS)
6:27 AM · Apr 7, 2024
·
115
Views
d_stock
@d_stock07734
On Tuesday, April 9, Rathmell will join a representative from the White House and other panelists to discuss the latest on President Joe Biden’s Cancer Moonshot initiative. This major symposium, The Cancer Moonshot: Opportunities to Fulfill the Vision of the National Cancer Plan, will be held from 2:30 – 4 p.m. PT in Room 1 on the upper level of the convention center.
The Cancer Moonshot: Opportunities to Fulfill the Vision of the National Cancer Plan - Dedicated to the Memory of Senator Dianne Feinstein
Description De Reignited Cancer Moonshot, gelanceerd door president Biden, heeft tot doel middelen te mobiliseren en partnerschappen te smeden in de strijd tegen kanker met als doel het sterftecijfer door kanker binnen 25 jaar met de helft te verminderen en het leven van zowel mensen met kanker als overlevenden van kanker te verbeteren. Als onderdeel van de Moonshot heeft het National Cancer Institute (NCI) een gedurfde routekaart geschetst, het National Cancer Plan, om onderzoeks- en interventiestrategieën te bevorderen om de preventie, detectie en behandeling van kanker te verbeteren en de ongelijkheid in kanker te verminderen. De historische tweeledige steun in het Congres voor federale financiering van biomedisch onderzoek is echter op tragische wijze uitgehold. Als gevolg hiervan worden biomedische onderzoekers momenteel geconfronteerd met een crisis. Het budget van de National Institutes of Health (NIH) stagneert voor het eerst in acht jaar, waardoor verdere vooruitgang tegen kanker en een groot aantal andere ziekten en gezondheidsuitdagingen in gevaar komt.
Deze sessie op de jaarlijkse AACR-bijeenkomst biedt de leiding van NCI de gelegenheid om recente doorbraken in de kankerwetenschap en de belofte van het National Cancer Plan te bespreken. Dit zal worden gevolgd door een discussie door verschillende leiders in het veld over de enorme kansen in kankeronderzoek en de noodzaak van een gezamenlijke inspanning om het Congres te informeren over het belang van voortdurende robuuste investeringen in NIH en NCI. https://abstractsonline.com/pp8/#!/20272/session/57
https://aacrmeetingnews.org/news/new-nci-director-to-address-annual-meeting-discuss-biden-cancer-moonshot/
7:32 AM · Apr 7, 2024
·
100
Views
Thanks for the update Captain.
GLTU
It will then take about 5 years before they announce the 5-year OS.
OS is the gold standard aslo for the FDA.
Then I think we already have a cure with the combos.
You are right.
My bad, sorry.
Moderator, please remove that post.
Thanks Captain.
GLTU
Gregory Zivic, MD
@metacollectiveG
$NWBO It’s my contention MHRA were working with the company before submission as a test case for the guidance they put out in Jan. asking that co’s. with novel treatments engage with MHRA during MAA draft to avoid RFIs or rejections and speed approvals. I believe we’re real close
Thanks Peter:
Cancer Moonshot Aims to Expand Research, Early Detection, and Equity
https://www.targetedonc.com/view/cancer-moonshot-aims-to-expand-research-early-detection-and-equity
GLTU
Peter Davis
Thanks d_stock.
living search engine.
GLTU
d_stock
@d_stock07734
Size exclusion chromatography (SEC) is the analytical “gold standard” for the separation and accurate quantitation of aggregates, monomers, and lower molecular weight fragments contained in biotherapeutic peptides and proteins, including monoclonal antibody (mAbs) drugs.
Did Dr. Liau use SEC in her research? Sure did.
https://ncbi.nlm.nih.gov/pmc/articles/PMC2818760/pdf/nihms165905.pdf
"For enzyme assays using recombinant IDH1 enzyme, proteins were purified from E coli using Ni affinity and size-exclusion chromatography."
The interesting part is that all these BPs are recruiting people with skills on SEC.
Merck
Principal Scientist, Biologics Analytical Research & Development
https://jobs.merck.com/us/en/job/R281389/Principal-Scientist-Biologics-Analytical-Research-Development
Extensive experience in analysis of biologics (separation methods such as Size Exclusion Chromatography (SEC), Ion Exchange Chromatography (IEX) and Capillary Electrophoresis (CE) techniques, and immunoassays such as residual and PCR-based assays).
AMGEN
Process Development Associate
https://biospace.com/job/2874322/process-development-associate
Performing analytical testing in the realm of chromatography and electrophoresis involves various techniques to separate, identify, and quantify components within a sample most including the techniques below:
Size Exclusion Chromatography (SEC)
Reduced Capillary Electrophoresis (rCE-SDS)
Non-Reduced Capillary Electrophoresis (nrCE-SDS)
Astrazeneca
Senior Scientist, Bioconjugation
https://careers.astrazeneca.com/job/gaithersburg/senior-scientist-bioconjugation/7684/61310462272
Proficiency in analytical characterization techniques such as Hydrophobic Interaction Chromatography (HIC)-HPLC, Size Exclusion Chromatography (SEC), Liquid Chromatography–Mass Spectrometry (LC-MS), Ion-Exchange (IEX), and Reversed Phase (RP)-HPLC.
Takeda
Senior Research Associate
https://glassdoor.com/job-listing/senior-research-associate-takeda-pharmaceuticals-JV_IC1154599_KO0,25_KE26,48.htm?jl=1008450619804
Analyze protein aggregation by Size Exclusion chromatography (SEC)
Bristol Myers Squibb
Scientist Protein Expression and Purification
https://linkedin.com/jobs/view/scientist-protein-expression-and-purification-at-bristol-myers-squibb-3834016179/
Perform mini to mid-scale purifications using different kinds of chromatography (affinity, ion exchange, size exclusion and hydrophobic interaction chromatography) and be responsible for purification process design, optimization and troubleshooting if needed
Regeneron
Sr. Assoc. Scientist Protein Biochemistry
https://glassdoor.com/job-listing/sr-assoc-scientist-protein-biochemistry-regeneron-pharmaceuticals-inc-JV_IC1132438_KO0,39_KE40,69.htm?jl=1009076902423
Fundamental technical competencies in key analytical protein methodologies such as Size Exclusion Chromatography (SEC), UV-Vis spectrophotometry, SDS-PAGE, Western blotting, CE-SDS, protein purification and basic chemistry skills as applied toward protein modifications.
Abbvie
2024 Biologics Drug Product Development Intern
https://biospace.com/job/2883970/2024-biologics-drug-product-development-intern/?utm_campaign=google_jobs_apply&utm_source=google_jobs_apply&utm_medium=organic
Identify relative risk of protein adsorption and degradation under various formulation conditions using analytical techniques, such as: quartz crystal microbalance with dissipation (QCM-D); size exclusion chromatography (SEC); particle characterization (micro-flow imaging); and ion-exchange chromatography (IEX)
Eli lilly
Advisor / Sr. Advisor - Separation Science and Mass Spectrometry - Bioproduct Research and Development
https://careers.lilly.com/us/en/job/R-62167/Advisor-Sr-Advisor-Separation-Science-and-Mass-Spectrometry-Bioproduct-Research-and-Development?utm_campaign=google_jobs_apply&utm_source=google_jobs_apply&utm_medium=organic
Experience with chromatographic separations (reversed phase chromatography, ion exchange chromatography, size exclusion chromatography, affinity chromatography), capillary electrophoresis, and other methods for the analysis of oligonucleotides, peptides, and other biomolecules.
J&J
SENIOR SCIENTIST PROTEIN SCIENCES
https://johnsonjohnson.ongig.com/jobs/r-d/-san-diego-california-united-states/senior-scientist-protein-sciences/6830190611#/
Proficiency in use of LCMS, liquid chromatography (including HPLC, affinity purification, size exclusion chromatography, ion exchange chromatography), and associated data analysis is required.
Peter Davis
@peter_brit
#dcvax $nwbo #gbm
Market Access and HTA - a snapshot of recent developments....
9 FEB 2024
What happened that surprised you over these months?
I was definitely surprised by the announcement regarding the establishment of the Canadian Drug Agency (CDA) to replace the Canadian Agency for Drugs and Technologies in Health (CADTH). In the announcement there was a big focus on the increasing use of real-world data collection across Canada to improve decision making, so it will be interesting to see how this is done in the future. It perhaps reflects a Canadian view to utilize health technology management (i.e., dynamic rather than static HTA).
"The UK’s Innovative Medicine’s Fund and France’s Direct Access Scheme there appears to be a global aim to improve access to medicines and promote innovation which should be seen as a positive sign for the pharmaceutical industry"
https://evidencebaseonline.com/market-access-and-hta-a-snapshot-of-recent-developments-with-sreeram-ramagopalan-september-december-2023/
Thank you Sojo .
GLTU
Thanks d_stock.
d_stock
@d_stock07734
In Nature preprint, Dr. Liau did analysis on scRNA-seq.
Dendritic Cell Vaccination in Conjunction with TLR Agonist Polarizes Interferon Immune Responses Associated with Long-term Survival in Malignant Glioma Patients [scRNA-seq]
https://ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE237579
What is scRNA-seq? Here is the answer from ChatGPT.
Single-cell RNA sequencing (scRNA-seq) is a powerful technique used in molecular biology to analyze the gene expression profiles of individual cells within a heterogeneous population. In the context of tumors, scRNA-seq allows researchers to study the complex cellular composition and heterogeneity present within the tumor microenvironment.
Tumors are not homogeneous masses of identical cells but rather consist of various cell types, including cancer cells, immune cells, stromal cells, and others. Each of these cell types may contribute differently to tumor growth, metastasis, and response to therapy.
By using scRNA-seq, researchers can identify and characterize the different cell types present in a tumor, as well as understand their gene expression patterns, interactions, and functional states. This information is crucial for deciphering the mechanisms underlying tumor development, progression, and response to treatment.
Some of the key applications of scRNA-seq in tumor research include:
Cellular Heterogeneity: Revealing the diverse cell populations within tumors and understanding how they contribute to tumor growth, metastasis, and therapy resistance.
Tumor Microenvironment: Characterizing interactions between cancer cells and non-cancerous cells (e.g., immune cells, fibroblasts) in the tumor microenvironment and how these interactions influence tumor progression.
Identification of Biomarkers: Discovering novel biomarkers associated with specific tumor subtypes, disease progression, or response to therapy, which can potentially be used for diagnosis, prognosis, and treatment stratification.
Therapeutic Targets: Identifying new therapeutic targets by pinpointing molecular pathways that are dysregulated in specific cell populations within the tumor.
Drug Resistance Mechanisms: Investigating mechanisms of drug resistance at the single-cell level, which can inform the development of more effective therapeutic strategies.
Overall, scRNA-seq provides a comprehensive and high-resolution view of the cellular landscape within tumors, enabling deeper insights into tumor biology and the development of more personalized and targeted cancer therapies.
3:12 AM · Mar 29, 2024
·
288
Views
annie post
@apwriter
·
18h
$nwbo. Discovery will be fun.
“Yahoo! warns users of its message boards that their identities can be traced, and that it will reveal their identifying information when legally compelled to do so.”
@adamfeuerstein
You in trouble boy.
@stanews
Quote
Dr. Thomas Ichim
@exosome
·
21h
Interesting read regarding going after bashers
$tsoi $nwbo
https://caselaw.findlaw.com/court/ca-court-of-appeal/1249034.html
How on earth is it possible that investors allow themselves to be deceived by such a press release:
" Nevercure stock surged Wednesday after its medtech device nearly doubled the length of time patients with brain tumors lived before worsening ".
So the PFS has doubled but the 2nd endpoint, OS, has not been reached.
Wow, great.
You will get cancer but you will not live any longer!
Only the return of the cancer takes a little longer.
What a great result! (cynical).
And then the pumping by those fantastic "analysts".
The investors are being fooled in an insane way by these scammers.
Thank you StonkMaster and Henry.
Great news again.
GLTU
Thanks Captain.
It is quiet at the front.
Could it be the calm before the storm?
GLTU
Thanks for your answer.
Since you always lie, I now know for sure that it is 150 calendar days.